Gene Panel Market By Product Type (Preconfigured Panels, Customized Panels); By Technique (Amplicon-Based, Hybridization-Based); By Application (Cancer Risk Assessment, Inherited Disease Testing, Pharmacogenomics, Carrier Screening, Others); By End User (Hospitals & Diagnostic Labs, Academic & Research Institutions, Biopharmaceutical Companies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

1. Introduction and Strategic Context

The Global Gene Panel Market will witness a robust CAGR of 11.3% , valued at $4.2 billion in 2024 , and is expected to appreciate and reach $7.87 billion by 2030 , confirms Strategic Market Research .

Gene panels are targeted groups of genes analyzed simultaneously to detect mutations associated with inherited or acquired diseases. These panels are integral to precision medicine, enabling faster diagnosis, better therapeutic targeting, and cost-effective genetic testing. As of 2024, their applications range from oncology and cardiology to rare disease diagnostics and pharmacogenomics.

The increasing global emphasis on personalized medicine , the rising prevalence of genetic disorders , and technological advances in next-generation sequencing (NGS) have made gene panels strategically indispensable. Regulatory incentives for companion diagnostics and the growing demand for early diagnosis are accelerating their clinical adoption across hospitals, research institutes, and diagnostic labs.

A significant macro force reshaping the gene panel market is the integration of AI and bioinformatics platforms that streamline variant interpretation, reduce turnaround times, and improve clinical decision-making. Further, regulatory harmonization , especially in the U.S. and Europe, is encouraging the commercialization of lab-developed tests and CE-IVD marked panels.

Key stakeholders driving the ecosystem include:

• Diagnostic equipment OEMs (e.g., manufacturers of sequencing and microarray systems)
• Clinical laboratories and hospital networks
• Pharmaceutical and biotech companies leveraging gene panels in drug development
• Regulatory agencies like the FDA and EMA
• Investors and VCs , increasingly active in genomics and diagnostics

With population-scale sequencing projects underway in countries like the UK, China, and the U.S., the role of gene panels in public health genomics and personalized preventive care is poised to expand rapidly. The next frontier is in multi-analyte panels , liquid biopsy integration, and real-time monitoring, reshaping both diagnostics and therapeutic strategy alignment.

2. Market Segmentation and Forecast Scope

The global gene panel market is segmented across four primary dimensions: By Product Type , By Technique , By Application , and By End User , with regional insights spanning North America, Europe, Asia-Pacific, and LAMEA .

By Product Type

• Preconfigured Gene Panels
• Customized Gene Panels

Preconfigured panels dominate the market, accounting for 62.4% of global revenue in 2024 , owing to their clinical validation and immediate deployability in diagnostic workflows. However, custom gene panels are the fastest-growing segment, driven by the increasing demand for precision testing in rare diseases and targeted oncology . Researchers and clinicians prefer customized panels when standard panels fail to capture rare or ethnically specific variants.

By Technique

• Amplicon-Based Sequencing
• Hybridization-Based Sequencing

Amplicon-based techniques are widely used in research and low-input DNA applications, offering quicker turnaround and cost-effectiveness. However, hybridization-based sequencing is gaining preference in clinical settings due to its superior coverage, especially for detecting large genomic rearrangements. As reimbursement frameworks improve, clinical labs are shifting toward hybridization techniques for higher diagnostic accuracy.

By Application

• Cancer Risk Assessment
• Inherited Disease Testing
• Pharmacogenomics
• Carrier Screening
• Other Applications

Cancer risk assessment represents the largest application segment in 2024, particularly in breast, ovarian, colorectal, and prostate cancers. The availability of hereditary cancer panels (e.g., BRCA1/2, TP53, MLH1) has driven adoption in both oncology clinics and preventive health centers . However, pharmacogenomics is projected to grow at the highest CAGR through 2030, propelled by its integration into electronic health records and growing payor support for companion diagnostics.

By End User

• Hospitals and Diagnostic Laboratories
• Academic and Research Institutions
• Biopharmaceutical Companies

Hospitals and diagnostic labs constitute the majority share, leveraging gene panels for early diagnosis, treatment decision-making, and patient stratification. High-throughput capacity and integration with LIS/EMR systems make them ideal environments for routine genetic screening. Meanwhile, biopharma companies are increasingly utilizing gene panels for patient recruitment in clinical trials and biomarker discovery , especially in immuno-oncology and neurology.

By Region

• North America
• Europe
• Asia Pacific
• LAMEA (Latin America, Middle East & Africa)

In 2024, North America leads the global market, benefiting from advanced healthcare infrastructure, favorable reimbursement policies, and the presence of leading genomics firms. However, Asia Pacific is the fastest-growing region, driven by rising genomic literacy, increased government funding (e.g., China’s Precision Medicine Initiative), and expanding private sector diagnostics.

The interplay between technical customization and clinical scalability is shaping the segmentation dynamics of the gene panel market. Vendors are now offering modular platforms and menu-based configurations to bridge both ends of this demand spectrum.

3. Market Trends and Innovation Landscape

The gene panel market is experiencing rapid evolution driven by technological breakthroughs, convergence of AI with genomics , and an escalating demand for clinical-grade genetic insights . Innovation spans the entire value chain—from panel design and sequencing to data interpretation and clinical reporting.

1. Rise of AI-Powered Variant Interpretation Platforms

A major trend reshaping the landscape is the integration of AI and machine learning tools to assist in variant classification and report generation . Platforms such as SOPHiA GENETICS, Fabric Genomics, and Deep Genomics are enhancing the speed and accuracy of clinical interpretations. These tools reduce the burden on genetic counselors , enabling faster diagnosis and improving physician confidence in test results.

In addition, AI is also being used to predict variant pathogenicity and uncover non-coding regulatory variants , which were previously ignored in panel-based approaches. This shift opens new doors in pharmacogenomics and complex disease diagnostics.

2. Transition Toward Multi-Omics and Integrated Panels

While traditional panels focused solely on DNA, the trend is now moving toward multi- omic integration —combining genomics with transcriptomics and proteomics. Vendors are beginning to launch panels that include RNA-based fusion detection (e.g., ALK, ROS1) and epigenetic markers relevant in tumor profiling. This evolution is especially transformative in oncology, where a single test can inform prognosis, treatment response, and resistance mechanisms.

Another trend is the growth of liquid biopsy-compatible gene panels , which allow non-invasive genomic profiling from blood, saliva, or urine. This is particularly beneficial for monitoring tumor evolution, recurrence risk, and therapy adjustments.

3. Modular and Disease-Agnostic Panel Design

Vendors are increasingly shifting to modular panel platforms , where clinicians can customize a panel by choosing gene sets from a curated catalog . This enables scalability and adaptability across disease domains. Companies are responding to a growing need for disease-agnostic testing workflows that serve undiagnosed rare disease cases or multi-system disorders.

4. Regulatory Alignment and Accelerated Approvals

In the U.S., the FDA’s creation of new frameworks for in vitro diagnostic tests (IVDs) and breakthrough device designations has accelerated the commercialization of clinically validated panels. The European market is undergoing transformation under the IVDR (In Vitro Diagnostic Regulation) , which mandates more rigorous evidence for clinical performance. Despite regulatory hurdles, these changes are pushing manufacturers to prioritize test quality, reproducibility, and clinical utility.

5. Collaborations and Strategic Alliances

Key market players are entering strategic partnerships to strengthen innovation pipelines and market reach. Notable trends include:

• Joint ventures between NGS platform providers and biopharma companies to co-develop companion diagnostics
• Academic partnerships to study population-specific variant prevalence
• M&A activity targeting bioinformatics firms and regional testing labs

Such alliances are pivotal in unlocking new revenue models, particularly subscription-based access to variant databases and analytics-as-a-service platforms.

As we move into the next decade, the gene panel industry is expected to be defined by ecosystem consolidation, automation, and patient-centric innovation. Agile companies that embrace clinical interoperability and hybrid (DNA/RNA) diagnostics will lead the next wave of growth.

4. Competitive Intelligence and Benchmarking

The gene panel market is highly dynamic and moderately fragmented, characterized by a mix of global diagnostic giants, specialized genomic testing firms, and emerging platform innovators. These companies differentiate themselves through assay accuracy, customization capabilities, turnaround time, and regulatory compliance . Strategic collaborations, product expansion, and geographic outreach remain the core pillars of competition.

1. Illumina, Inc.

As a market-defining leader in sequencing platforms , Illumina plays a central role in enabling gene panel testing, particularly through its TruSight panels . The company’s strength lies in its vertically integrated ecosystem , spanning instruments, reagents, and software. Illumina has focused on clinical-grade panels for oncology and rare diseases , targeting hospital labs and reference diagnostic centers . Its acquisition of GRAIL and investment in liquid biopsy platforms further strengthens its downstream capabilities.

Illumina’s strategy emphasizes innovation scale and regulatory readiness, especially in the U.S. and EU markets.

2. Thermo Fisher Scientific

Thermo Fisher offers a broad portfolio of NGS-based and qPCR-based gene panels , with strong customization features. It serves both research and clinical users , and has partnered with pharma companies for companion diagnostics development . Its Ion Torrent technology and Oncomine panels are widely used in precision oncology.

The company's competitive edge stems from its ability to integrate instrument hardware, cloud-based analytics, and global distribution networks.

3. Agilent Technologies

Agilent specializes in hybridization-based gene panels and excels in target enrichment and sample prep kits . The company’s SureSelect and HaloPlex products are widely adopted in both germline and somatic mutation testing. Agilent maintains strong ties with academic institutions and contract research organizations (CROs), and continues to invest in bioinformatics software for variant calling and annotation .

Agilent’s approach is deeply rooted in accuracy and customization flexibility, positioning it well in research and translational medicine settings.

4. F. Hoffmann-La Roche Ltd.

Roche , through its subsidiary Foundation Medicine , offers one of the most advanced comprehensive genomic profiling platforms , used globally in oncology diagnostics. Roche is also integrating its diagnostics arm with real-world data platforms and EMR-linked genomic repositories , creating a full-service ecosystem for clinicians and payors.

By leveraging pharmaceutical synergies and a strong regulatory track record, Roche commands a powerful position in hospital-based and commercial diagnostics.

5. QIAGEN N.V.

QIAGEN provides gene panels for infectious disease , oncology , and hereditary testing , often bundled with its QIAseq and QIAcube systems. The company has a growing footprint in emerging markets, focusing on workflow automation and bioinformatics integration . Its collaboration with Illumina for NGS content delivery on Illumina sequencers is a strategic differentiator.

QIAGEN’s core strengths include standardized workflow, reagent quality, and regional scalability.

6. Invitae Corporation

A leader in direct-to-consumer and physician-ordered gene panels , Invitae has built a competitive niche in affordable hereditary disease testing . The firm is vertically integrated, with its own variant interpretation pipeline, genetic counseling services, and subscription models for patient monitoring. Despite recent financial restructuring, Invitae remains influential in democratizing access to genetic testing.

Invitae’s consumer-centric approach and emphasis on whole-life genetic care set it apart from traditional diagnostic players.

7. ArcherDx (A part of Integrated DNA Technologies / Danaher)

ArcherDx , now under Danaher Corporation , is known for its RNA-based fusion panels and solid tumor profiling kits , particularly suited for precision oncology. Its technology is widely used in clinical trials and translational research . ArcherDx’s seamless integration with data analytics tools makes it a go-to provider for labs seeking end-to-end testing solutions.

Danaher’s acquisition has given ArcherDx financial scale and operational leverage to compete globally with larger diagnostics firms.

Across the board, successful competitors in this market combine deep technical know-how with streamlined regulatory navigation, real-time analytics, and integrated customer education. The move toward multi- omic panels, reimbursement-backed clinical utility, and digital delivery platforms is the new battleground for differentiation.

5. Regional Landscape and Adoption Outlook

The regional dynamics of the global gene panel market are shaped by a combination of regulatory maturity, healthcare infrastructure, reimbursement systems , and genomic literacy . While North America dominates in terms of revenue and clinical deployment, Asia Pacific is emerging as a high-growth frontier due to rising investment and increased demand for precision diagnostics.

North America

North America , led by the United States , represents the largest regional market, accounting for over 42% of global revenue in 2024 . The U.S. healthcare system has rapidly integrated gene panels into oncology, reproductive health, and pharmacogenomics testing, driven by:

• Favorable reimbursement under CMS and private insurers for hereditary cancer panels and companion diagnostics
• Widespread clinical NGS adoption through hospital networks and commercial labs like Labcorp and Quest Diagnostics
• Strong regulatory support, including FDA’s Breakthrough Devices Program for advanced genomic tests

Canada also demonstrates growing uptake, especially via provincial precision medicine initiatives and integration into public healthcare models.

With robust bioinformatics infrastructure, academic partnerships, and pharma-driven demand for biomarker validation, North America is expected to maintain its leadership through 2030.

Europe

Europe is a mature but heterogeneous market. Countries such as Germany, the UK, and France are at the forefront of clinical gene panel usage, particularly in oncology and rare diseases. Key market drivers include:

• The rollout of population-wide genomic screening initiatives , such as Genomics England and France Genomique
• Compliance with the new IVDR framework , which has prompted investments in clinical validation and CE-IVD approved panels
• National reimbursement mechanisms that are increasingly supporting multi-gene testing protocols

Eastern European nations, while lagging in infrastructure, are gradually opening up through EU funding and tele-genomics partnerships.

Overall, Europe’s strict regulatory environment is encouraging quality-focused innovation and greater standardization of clinical workflows.

Asia Pacific

Asia Pacific is the fastest-growing regional market, projected to expand at a CAGR exceeding 14% from 2024 to 2030 . Growth is driven by:

• Massive investments in genomics infrastructure, such as China’s Precision Medicine Initiative and India’s GenomeIndia project
• Rising consumer demand for direct-to-consumer and preventive genetic testing
• Expanding private sector diagnostic chains and corporate wellness programs
• Improvements in genetic counseling and data interpretation capacity , especially in Japan, South Korea, and Singapore

Countries like China and South Korea are developing national genomic databases and AI-powered interpretation platforms, enhancing their competitiveness.

Asia Pacific is not only a consumption hub but also an emerging innovation zone for customizable panels and localized variant databases.

LAMEA (Latin America, Middle East, and Africa)

While currently underpenetrated, LAMEA offers a compelling white-space opportunity:

• Brazil and Mexico are leading adoption in Latin America through academic-led initiatives and partnerships with global diagnostics firms
• Middle Eastern countries like Saudi Arabia and UAE are investing in genomics as part of national health vision plans (e.g., Vision 2030)
• In Africa , adoption remains low due to lack of infrastructure, but pilot projects are underway in South Africa and Kenya for carrier screening and infectious disease genotyping

The major constraint in LAMEA is affordability and the absence of a clear reimbursement structure. However, public-private collaborations are starting to reshape the outlook.

Across regions, the success of gene panels depends on not just technical superiority but also localization, cost-effectiveness, and integration with clinical decision systems. Regional leaders are those who can balance scientific rigor with scalable deployment in real-world healthcare settings.

6. End-User Dynamics and Use Case

The utility of gene panels spans a wide range of end-users, each leveraging the technology for distinct clinical or research goals. Adoption dynamics are shaped by test throughput needs, turnaround times, level of diagnostic complexity, and availability of genetic counseling infrastructure.

Hospitals and Diagnostic Laboratories

Hospitals and diagnostic labs account for the largest end-user segment , driven by their role in clinical diagnostics , especially in oncology, cardiology , and inherited disease screening . High-volume labs benefit from:

• Integration with electronic medical records (EMRs) and laboratory information systems (LIS)
• Established sample processing workflows and bioinformatics support
• Reimbursement mechanisms that incentivize multi-gene testing in symptomatic patients

Academic hospitals and cancer centers often adopt gene panels for risk assessment , prognostic testing , and treatment decision-making , particularly in breast, colorectal, and lung cancers.

These institutions are at the forefront of applying clinical-grade panels for real-time patient management and multidisciplinary case reviews.

Academic and Research Institutions

Academic centers and research institutions use gene panels primarily for translational studies , genome-wide association studies (GWAS) , and rare disease discovery . Unlike clinical settings, research users emphasize:

• Customization and flexibility in panel design
• High-throughput sequencing for population studies
• Advanced data analytics for exploratory variant identification

In particular, centers working on neurogenetics , immunogenomics , and reproductive genetics prefer targeted panels as a cost-effective bridge between microarrays and whole-exome sequencing.

Academic users often shape early-stage innovation, which later migrates into the clinical mainstream through published validation studies and pilot programs.

Biopharmaceutical and Biotechnology Companies

Biopharma companies are increasingly using gene panels in clinical trials , biomarker discovery , and companion diagnostics development . Applications include:

• Patient stratification for targeted therapies
• Monitoring resistance mutations during drug development
• Identification of novel drug targets via genotype-phenotype correlation

These companies collaborate with diagnostic labs to co-develop regulatory-grade assays aligned with FDA and EMA requirements. Panels are frequently bundled into precision medicine programs alongside real-world data and digital biomarkers.

Biotech firms working in immuno-oncology and gene therapy are particularly active in using panels for eligibility screening and treatment monitoring.

✅ Use Case: Precision Oncology in a Tertiary Korean Hospital

A tertiary hospital in Seoul, South Korea, implemented a 52-gene cancer panel for early-stage lung cancer patients. Previously reliant on single-gene assays for EGFR and ALK mutations, the institution faced delays in therapy initiation due to sequential testing and missed rare mutations.

By adopting a custom hybrid-capture panel validated for East Asian mutation frequencies, the hospital reduced turnaround time from 21 days to 7 days, increased detection rates for actionable mutations by 23%, and enabled enrollment into two precision therapy trials within a six-month period.

The initiative was supported by the South Korean government’s Precision Medicine Hospital Program, demonstrating how policy alignment and lab innovation can jointly improve outcomes.

End-user adoption is accelerating as gene panels become more integrated into routine workflows, offering rapid answers for complex diagnostic questions. Their adaptability to both high-throughput and point-of-care settings ensures continued relevance across diverse user profiles.

7. Recent Developments + Opportunities & Restraints (Short Section)

🆕 Recent Developments (Past 2 Years)

• Illumina launched a pan-cancer gene panel with companion diagnostics support, enabling broader clinical use in solid tumors .
• Roche's Foundation Medicine received FDA approval for its liquid biopsy gene panel to detect mutations from blood samples.
• Thermo Fisher Scientific and Pfizer announced a partnership to co-develop gene panels for oncology drug trials.
• Agilent Technologies acquired Avida Biomed , expanding its capabilities in multiplex gene panel testing for targeted cancer profiling.
• South Korea launched a national project to integrate hereditary cancer panels into its National Health Insurance scheme.

🔁 Opportunities

• Expansion of companion diagnostics : Regulatory momentum and pharma partnerships are creating demand for co-developed gene panels linked to precision therapies.
• Emerging markets : Asia Pacific, Latin America, and Middle East countries are building genomics infrastructure, opening new avenues for panel-based diagnostics.
• AI-enhanced variant interpretation : Integrating machine learning into panel reporting systems improves accuracy, reduces turnaround, and addresses the shortage of genetic counselors .

🚫 Restraints

• High cost of clinical-grade gene panels : Particularly in low-income countries, the upfront and validation costs remain prohibitive without reimbursement.
• Complex regulatory environment : Divergent standards across geographies (e.g., FDA vs. IVDR) slow global expansion and require extensive documentation.

The future growth of gene panels depends on how rapidly innovators and regulators can align technology, policy, and payer frameworks. Companies that scale through affordability, automation, and real-world evidence will gain strategic edge.